30 research outputs found
A branching, positive relief network in the middle member of the Medusae Fossae Formation, Equatorial Mars - evidence for sapping?
The Medusae Fossae Formation (MFF) is a geological formation comprising three geological units (members) spread across five principal lobes. It dominates a quarter of the longitudinal extent of the equatorial region of Mars. Positive relief features referred to as ‘sinuous ridges' (commonly interpreted as inverted paleoflow channel or valley fills) have been observed in the lowest member of the western MFF, but have not been identified within the central and eastern portions of the formation, in the middle and upper members. This paper presents the identification and analysis of a branching, positive relief system which occurs in the central lobe of the MFF in what appears to be an exposure of the middle member. A simple geomorphological map of the system is presented, from which we have adopted the working hypothesis that this is an inverted fill of a branching fluvial channel or valley system. A suite of morphological and topographic evidence supporting this hypothesis is presented, including analysis of the network using a~15 m per pixel digital terrain model derived from a Context Imager (CTX) stereo image pair. The evidence supporting this hypothesis includes: 1) The local slope and topography of the upper surface of the network are consistent with a contributory network, 2) The braided, fan-like form at the termination of the branching network is consistent in morphology with it being a depositional fan at the end of a fluvial system, 3) The terminal fan and surrounding deposits show layering and polygonization, 4) There is strong association between the lower order branches and amphitheater shaped scarps in the depression walls. We evaluate the possible origins of this fluvial system and suggest that seepage sapping is the most probable. Two possible models for the evolution of the network and related features are presented; both require melt of ice within the MFF to form liquid water. We conclude that at least some portions of the Medusae Fossae Formation, if not the entire formation, were once volatile-rich. Finally, we note that our observations do not rule out the case that this network formed before MFF emplacement, and has since been exhumed. However, this conclusion would suggest that much of the surrounding terrain, currently mapped as middle-member MFF, is not in fact MFF material at all
Copper Metallurgy in the Jordan Valley from the Third to the First Millennia BC: Chemical, Metallographic and Lead Isotope Analyses of Artefacts from Pella
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Background:
In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.
Methods:
This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936).
Findings:
Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001).
Interpretation:
In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids.
Funding:
UK Research and Innovation (Medical Research Council) and National Institute of Health Research
Ciguatera in Australia - occurrence, clinical-features, pathophysiology and management
Ciguatera is a type of food poisoning that results from eating certain tropical fish which have become toxic. It is common in Australia: 175 outbreaks, which involved 527 people, were reported in Queensland between 1965 and 1984. It seems restricted to certain areas around the Australian coastline. Most reports have involved the narrow-barred Spanish mackerel, Scomberomorus commersoni, most of which were caught in southern Queensland waters. Up to 2100 cases may have occurred in north Queensland between 1965 and 1984, which were not recorded by the writers. The symptoms of ciguatera in Australia are similar to those reported elsewhere in the South Pacific. Ciguatoxin acts by increasing the permeability of excitable membranes to sodium ions. This type of membrane is found throughout the body in nerve tissue as well as in heart and skeletal muscle. The treatment of ciguatera remains symptomatic and supportive only. Major advances in treatment for ciguatera and detection of ciguatoxin await the means of producing additional ciguatoxin